 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
28 News |  |
- ALG.APV-527 / Alligator Biosci, Aptevo Therap
Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4 x 4 (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1281;
APV-527 treatment demonstrates good tolerability, safety, biological activity, and prolonged SD in some patients suggesting clinical benefit of treatment. Upon determining the optimized dose, subsequent development will likely take place as a combination treatment.
- |||| ALG.APV-527 / Alligator Biosci, Aptevo Therap
New P1/2 trial, Metastases: ALG.APV-527-101: ALG.APV-527 First-in-human Study (clinicaltrials.gov) - Jul 7, 2023
P1/2, N=56, Recruiting, Sponsor: Aptevo Therapeutics
- | ALG.APV-527 / Alligator Biosci, Medexus
Preclinical, Journal: The bispecific tumor antigen-conditional 4-1BB x 5T4 agonist, ALG.APV-527, mediates strong T cell activation and potent anti-tumor activity in preclinical studies. (Pubmed Central) - Nov 8, 2022
ALG.APV-527 is uniquely designed for 5T4-conditional 4-1BB-mediated anti-tumor activity with potential to minimize systemic immune activation and hepatotoxicity while providing efficacious tumor-specific responses in a range of 5T4-expressing tumor indications as demonstrated by robust activity in preclinical in vitro and in vivo models. Based on the combined preclinical dataset, ALG.APV-527 has potential as a promising anti-cancer therapeutic for the treatment of 5T4-expressing tumors.
- || ALG.APV-527 / Alligator Biosci, Medexus
$APVO Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND https://t.co/LSZajdYddX (Twitter) - Sep 19, 2022
- ALG.APV-527 / Alligator Biosci, Medexus
ALG.APV-527: A 5T4 tumor directed bispecific approach utilizing ADAPTIRTM technology designed for conditional 4-1BB T cell/NK agonism against solid tumors (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_1122;
The unique design of the molecule minimizes systemic immune activation and hepatotoxicity, allowing for highly efficacious tumor-specific responses as demonstrated by potent activity in in vitro models. Based on these preclinical data, ALG.APV-527 is a promising anti-cancer therapeutic for the treatment of a variety of 5T4-expressing solid tumors and is progressing towards a phase I clinical trial in 2021.
- ALG.APV-527 / Alligator Biosci, Medexus, urelumab (BMS-663513) / BMS, Ono Pharma
[VIRTUAL] Potent tumor-directed T cell activation and in vivo tumor inhibition induced by a 4-1BB x 5T4 ADAPTIR™ bispecific antibody (virtual poster hall) - Nov 3, 2020 - Abstract #SITC2020SITC_2075;
APV-527 induces potent CD8+ T cell and NK cell co-stimulation and T-cell cytotoxicity and has potent in vivo anti-tumor activity, without inducing systemic toxicity. Based on preclinical data, ALG.APV-527 is a promising anti-cancer therapeutic for the treatment of a variety of 5T4-expressing solid tumors.
- ALG.APV-527 / Alligator Biosci, Medexus, urelumab (BMS-663513) / BMS, Ono Pharma
[VIRTUAL] Potent tumor-directed T cell activation and in vivo tumor inhibition induced by a 4-1BB x 5T4 ADAPTIR™ bispecific antibody (virtual poster hall) - Nov 3, 2020 - Abstract #SITC2020SITC_2011;
APV-527 induces potent CD8+ T cell and NK cell co-stimulation and T-cell cytotoxicity and has potent in vivo anti-tumor activity, without inducing systemic toxicity. Based on preclinical data, ALG.APV-527 is a promising anti-cancer therapeutic for the treatment of a variety of 5T4-expressing solid tumors.
- ALG.APV-527 / Alligator Biosci, Aptevo
Potent tumor-directed T cell activation and tumor inhibition induced by ALG.APV-527, a 4-1BB x 5T4 ADAPTIR™ bispecific antibody (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_1000;
ALG.APV-527 induces 5T4-dependent CD8+ T cell and NK co-stimulation, and has potent anti-tumor activity in a therapeutic model. Based on preclinical data, ALG.APV-527 is a promising anti-cancer therapeutic for the treatment of a variety of 5T4-expressing solid tumors.